한국유니온제약
080720KOSDAQ의약품 제조업64.0 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
Korea Union Pharmaceutical focuses on manufacturing and selling specialty pharmaceuticals, exporting finished drugs, and providing CMO (contract manufacturing) services. The company specializes in antibiotics, cardiovascular, and musculoskeletal products, leveraging its GMP facilities and R&D efforts to enhance profitability. It has expanded exports to regions such as the Middle East, Southeast Asia, and South America, and is further expanding its CMO business and product portfolio through a newly completed factory.
Number of Employees
123people
Average Salary
39.2M KRW
Score Calculation Basis
Detailed Financial Score
104.6x industry avg (excellent)
Half of industry avg (excellent)
Avg ▼23.9% (2-year basis)
Avg ▼92.6% (2-year basis)
Avg ROE 88.4% (improving, 3yr)
Detailed News Sentiment
- Neutral한국유니온제약, 감자 완료
한국유니온제약의 주식 감자 완료로 인해 발행주식 수와 자본금이 감소했으나, 직접적인 시장 영향은 제한적임.
Detailed Momentum
52w mid range (50%)
1m 0% (flat)
Volume flat
Detailed Disclosure
- Neutral[기재정정]주요사항보고서(감자결정)2026-07-23
- Neutral[기재정정]감자완료2026-07-23
- Positive[기재정정]주요사항보고서(유상증자결정)2026-07-22
- Neutral[기재정정]주요사항보고서(감자결정)2026-07-22
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-07-22
